Future Medicine is pleased to announce that, from January 2018, the eight journals within its Oncology Management Series - Breast Cancer Management, CNS Oncology, Colorectal Cancer, Hepatic Oncology, International Journal of Endocrine Oncology, International Journal of Hematologic Oncology, Lung Cancer Management and Melanoma Management, will be following a fully open access model.
"This is a very exciting step for our Oncology Management Series. Since the launch of these titles, we have continued to publish high-quality scientific research and commentary, and the open access model will allow us to share our excellent content with an even bigger audience," commented Roshaine Wijayatunga, Senior Editor for Oncology.
This transition means that all content published from January 2018 onwards will be open access on http://www.
The journals cover key areas of oncology, publishing the latest findings and opinions related to the overall management of the respective disease areas. They explore the best patient-centered clinical research and present this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journals also highlight significant advances in basic and translational research, placing them in context for future therapy.
The Oncology Management Series of journals considers original research articles that have been conducted with scientific rigor and research integrity. They also accept case report submissions. Other article types considered include reviews, perspectives, editorials and commentaries, providing oncologists and other health professionals with high-quality information and discussion on these widespread diseases in a clear, accessible format. Additionally, we also consider article proposals from nurse practitioners, patient advocates and the wider professional oncology community.
The journals will follow a gold open access model, publishing all articles under the Creative Commons CC-BY-NC-ND license. Authors are required to comply fully with the journal's Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. All research and review-style articles submitted to the journals will undergo double-blind peer review by a minimum of three independent experts.
We are currently actively soliciting contributions of original research, reviews and perspective articles. To submit an article or for any further information regarding article processing charges and policies, please contact the Senior Editor for Oncology, Roshaine Wijayatunga: email@example.com
For further information on our Oncology Management Series, please visit: https:/